LB Pharmaceuticals Inc Common Stock LBRX Balance Sheet Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| $250.17M+989% | $22.98M— | ||
| $45.04M+797% | $5.02M— | ||
| $770K+54.6% | $498K— | ||
| —— | $2.2M— | ||
| $308.43M+968% | $28.88M— | ||
| $1.58M-15.0% | $1.86M— | ||
| $2.15M-6.4% | $2.3M— | ||
| $312.93M+833% | $33.53M— | ||
| $2.13M-8.3% | $2.32M— | ||
| $4.59M-13.5% | $5.3M— | ||
| $730K+49.9% | $487K— | ||
| $7.44M-8.2% | $8.11M— | ||
| $2.84M-11.7% | $3.22M— | ||
| $3.57M-3.6% | $3.7M— | ||
| $11.62M-15.9% | $13.83M— | ||
| $3K+200% | $1K— | ||
| $430.67M+4,360% | $9.66M— | ||
| -$129.53M-24.2% | -$104.32M— | ||
| $168K+51.4% | $111K— | ||
| $301.31M+419% | -$94.55M-174% | ||
| $312.93M+833% | $33.53M— | ||
| $45.04M+797% | $5.02M— | ||
| $2.15M-6.4% | $2.3M— | ||
| $2.15M-6.4% | $2.3M— | ||
| $2.15M-6.4% | $2.3M— | ||
| $4.59M-13.5% | $5.3M— | ||
| $4.59M-13.5% | $5.3M— | ||
| $1.34M-46.4% | $2.5M— | ||
| $1.34M-46.4% | $2.5M— | ||
| $3.57M-3.6% | $3.7M— | ||
| $430.67M+4,360% | $9.66M— | ||
| $3K+200% | $1K— | ||
| $1.34M-46.4% | $2.5M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are LB Pharmaceuticals Inc Common Stock's total assets?
- LB Pharmaceuticals Inc Common Stock (LBRX) holds $393.5M in total assets.
- How much debt does LB Pharmaceuticals Inc Common Stock have?
- LB Pharmaceuticals Inc Common Stock carries $3.5M in total debt against $378.7M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does LB Pharmaceuticals Inc Common Stock have?
- LB Pharmaceuticals Inc Common Stock holds $320.7M in cash and equivalents.
- Can LB Pharmaceuticals Inc Common Stock cover its short-term obligations?
- Its current ratio is 35.68 — current assets exceed current liabilities.
- Where does LB Pharmaceuticals Inc Common Stock's balance sheet data come from?
- Every line is extracted from LB Pharmaceuticals Inc Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.